Stock OBI ONDINE BIOMEDICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ondine Biomedical Inc.

Equities

OBI

CA68234M2058

Market Closed - London S.E.
Other stock markets
 11:35:15 2024-07-12 am EDT 		5-day change 1st Jan Change
8.25 GBX 0.00% Intraday chart for Ondine Biomedical Inc. +3.12% -5.71%
Jun. 21 Stocks decline as service sector growth slows AN
Jun. 21 Ondine Biomedical celebrates Steriwave available via NHS Supply Chain AN

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
ONDINE BIOMEDICAL INC. Stock Ondine Biomedical Inc.
-5.71% 29.55M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.01% 181B
C+
MEDTRONIC PLC Stock Medtronic plc
-5.17% 100B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.97% 65.01B
A
HOYA CORPORATION Stock Hoya Corporation
+16.45% 45.75B
B+
DEXCOM, INC. Stock DexCom, Inc.
-7.28% 44.8B
B-
CENCORA, INC. Stock Cencora, Inc.
+8.64% 43.72B
B-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+12.70% 29.01B
B
TERUMO CORPORATION Stock Terumo Corporation
+17.98% 26.03B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-7.17% 24.28B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. OBI Stock
  4. Ratings Ondine Biomedical Inc.